Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
GSK stock jumps as insider Luke Miels named next CEO — can he deliver growth before HIV patent cliff hits?
GSK shares rise after naming Luke Miels as CEO-designate to succeed Emma Walmsley on Jan 1, 2026. Find out what investors expect next.
Biotech shake-up: can Dr. Ajay Ahuja’s appointment as CMO mark a turning point for MannKind?
Find out why MannKind (Nasdaq: MNKD) appointed Dr. Ajay Ahuja as chief medical officer and what this means for its pipeline and stock outlook.
Lupin deepens specialty push with VISUfarma acquisition: Can ophthalmology power its next European chapter?
Lupin acquires VISUfarma to expand into Europe’s ophthalmology market. Find out how this deal could reshape its specialty growth strategy.
Sen-Jam’s SJP-002C gets FDA-ready CMC milestone as investors eye late-stage trial momentum
Sen-Jam finalizes NDA-ready CMC deliverables for SJP-002C with KVK Tech and expands investor engagement, positioning for Phase 2b/3 trials.
Why Merus is the hottest takeover target in oncology right now—Genmab said to be frontrunner
Genmab is reportedly close to acquiring Merus in a high-stakes biotech deal that could reshape the oncology sector. Read the full breakdown now.
Can Alterity Therapeutics’ penny stock (ASX: ATH) ride ATH434’s $2.4bn market potential to long-term gains?
Alterity Therapeutics eyes $2.4B peak sales for ATH434 in Multiple System Atrophy. Can this small-cap biotech turn clinical promise into commercial reality?
Crinetics Pharmaceuticals shares soar after FDA clears Palsonify, the first oral acromegaly treatment
Crinetics shares surged after FDA approval of Palsonify, the first oral acromegaly therapy. Learn how this launch reshapes patient care and investor sentiment.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
Can vutrisiran set a new first-line standard in ATTR-CM after HELIOS-B trial results?
Alnylam’s HELIOS-B data shows vutrisiran cuts GI events by up to 49% in ATTR-CM, reinforcing its case as a first-line therapy. Read the full analysis.
Are Novo Nordisk layoffs, FDA scrutiny of Hims & Hers, and UnitedHealth profit squeeze reshaping the healthcare sector?
Novo Nordisk layoffs, Hims & Hers FDA warning, and UnitedHealth earnings headwinds shake the healthcare sector. See what investors need to know.